Founder
May 13th, 2005, 03:20 PM
by Warren Hopper
Legal Gear
Patent Pending M1P - FAQ
M1P is a close relative of a naturally occurring progestin that is currently used in medicine to treat male AIDS patients for muscle wasting and has been used safely for over 30 years. Read on for a list of commonly asked questions.
Gains
We expect a 30-60 day cycle of M1P to yield MUSCLE gains similar to “banned” prohormones. Users reported 10lb of lean muscle gain in 3 weeks, no side effects and massively increased strength. The gains are reported to be very dry, with almost no water weight or bloating do to the estrogen control complex (estrogen causes bloating in the body). This is due to the unique nature of M1P.
Shut Down
We expect shutdown to occur on a cycle between 30 to 60 days. Progestins act directly on the hypothalamus/pituitary in much the same way as steroids and reducing the pulsatile secretion of LH over time. The rate of LH decline with similar oral progestins can be variable and can take in excess of 60 days (1,2). So we should expect shutdown to occur somewhere between 30 and 60 days of continued use to be conservative. No matter what, to keep maximum gains, a PCT product like Formadrol Extreme should be used after every cycle.
Cholesterol Levels
We don’t expect cholesterol levels to be effected in normal use. While alterations in lipid profiles have been documented in women with the use of oral progestins, the changes were not evident until a dose of 200 mg or higher per day was administered (3). In men on similar oral progestins to M1P, total cholesterol levels were actually decreased with no changes in HDL cholesterol level (4).
Liver Toxicity
We expect no liver issues with M1P AT ALL! While M1P is methylated in the 6-alpha position to increase absorption, doses of a similar progestin of up to 600 mg did not increase levels of markers of liver damage such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) or bilirubin (5). M1P is a very mild compound on the liver and should not have any liver toxicity.
Coming soon the story of how it was made…
References
1. Guerin JF, Rollet J. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl. Jun;11(3):187-99, 1988
2. Turner L, Conway AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI, Handelsman DJ. Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab. Oct;88(10):4659-67, 2003
3. Teichmann AT, Wander HE, Cremer P, Wieland H, Kuhn W, Nagel GA, Seidel D. Medroxyprogesterone acetate and lipid metabolic changes. Arzneimittelforschung. May;37(5):573-7, 1987
4. Chen JJ, Berlin FS, Margolis S. Effect of large-dose progesterone on plasma levels of lipids, lipoproteins and apolipoproteins in males. J Endocrinol Invest. Aug;9(4):281-5, 1986
5. Telimaa S, Apter D, Reinila M, Ronnberg L, Kauppila A. Placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate. Eur J Obstet Gynecol Reprod Biol. Jul-Aug;36(1-2):97-105, 1990
Legal Gear
Patent Pending M1P - FAQ
M1P is a close relative of a naturally occurring progestin that is currently used in medicine to treat male AIDS patients for muscle wasting and has been used safely for over 30 years. Read on for a list of commonly asked questions.
Gains
We expect a 30-60 day cycle of M1P to yield MUSCLE gains similar to “banned” prohormones. Users reported 10lb of lean muscle gain in 3 weeks, no side effects and massively increased strength. The gains are reported to be very dry, with almost no water weight or bloating do to the estrogen control complex (estrogen causes bloating in the body). This is due to the unique nature of M1P.
Shut Down
We expect shutdown to occur on a cycle between 30 to 60 days. Progestins act directly on the hypothalamus/pituitary in much the same way as steroids and reducing the pulsatile secretion of LH over time. The rate of LH decline with similar oral progestins can be variable and can take in excess of 60 days (1,2). So we should expect shutdown to occur somewhere between 30 and 60 days of continued use to be conservative. No matter what, to keep maximum gains, a PCT product like Formadrol Extreme should be used after every cycle.
Cholesterol Levels
We don’t expect cholesterol levels to be effected in normal use. While alterations in lipid profiles have been documented in women with the use of oral progestins, the changes were not evident until a dose of 200 mg or higher per day was administered (3). In men on similar oral progestins to M1P, total cholesterol levels were actually decreased with no changes in HDL cholesterol level (4).
Liver Toxicity
We expect no liver issues with M1P AT ALL! While M1P is methylated in the 6-alpha position to increase absorption, doses of a similar progestin of up to 600 mg did not increase levels of markers of liver damage such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) or bilirubin (5). M1P is a very mild compound on the liver and should not have any liver toxicity.
Coming soon the story of how it was made…
References
1. Guerin JF, Rollet J. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl. Jun;11(3):187-99, 1988
2. Turner L, Conway AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI, Handelsman DJ. Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab. Oct;88(10):4659-67, 2003
3. Teichmann AT, Wander HE, Cremer P, Wieland H, Kuhn W, Nagel GA, Seidel D. Medroxyprogesterone acetate and lipid metabolic changes. Arzneimittelforschung. May;37(5):573-7, 1987
4. Chen JJ, Berlin FS, Margolis S. Effect of large-dose progesterone on plasma levels of lipids, lipoproteins and apolipoproteins in males. J Endocrinol Invest. Aug;9(4):281-5, 1986
5. Telimaa S, Apter D, Reinila M, Ronnberg L, Kauppila A. Placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate. Eur J Obstet Gynecol Reprod Biol. Jul-Aug;36(1-2):97-105, 1990